RESUMO
This study reviews free tissue transfer (FTT) surgery for both acute wound and reconstructive scar management of burn injuries at a UK burns unit over a 10-year period. Thirty eight patients underwent 46 FTTs, or free flaps, as part of their burn injury pathway. For the cohort of patients, there was one flap failure, which occurred for a secondary scar reconstruction. It is noted that FTT was successful for all seven acute or primary interventions. Anterolateral thigh flap was the most frequently performed (57%); followed by parascapular flaps (22%) of which 43% were pre-expanded. A method of pre-expansion for neck contractures and a novel technique of anchoring this flap to the pre-tracheal fascia are described here. This can provide the patient with good neck contouring by using the capsule to hitch the flap into a good position. It is clear that further work is required to study the prevention of hypertrophic scarring that can occur at the interface between flap and adjacent skin, where occurrence rate in this cohort was 17%. It is proposed that FTT now provides a viable solution both to the coverage of complex burn wounds and to the revision of scar contractures. Consensus over an FTT protocol for the primary management of open burn wounds is seen as the logical next step for this surgical intervention.
Assuntos
Queimaduras , Cicatriz Hipertrófica , Contratura , Retalhos de Tecido Biológico , Procedimentos de Cirurgia Plástica , Transplante de Pele , Queimaduras/cirurgia , Cicatriz Hipertrófica/etiologia , Cicatriz Hipertrófica/cirurgia , Contratura/etiologia , Contratura/cirurgia , Retalhos de Tecido Biológico/transplante , Humanos , Resultado do TratamentoRESUMO
Blinatumomab is a CD19/CD3 bispecific T-cell engager (BiTE®) antibody construct for treatment of leukemia. Transient elevation of cytokines (interleukin (IL)-6, IL-10, interferon-gamma (IFN-γ)) has been observed within the first 48 hours of continuous intravenous blinatumomab infusion. In human hepatocytes, blinatumomab showed no effect on cytochrome P450 (CYP450) activities, whereas a cytokine cocktail showed suppression of CYP3A4, CYP1A2, and CYP2C9 activities. We developed a physiologically based pharmacokinetic (PBPK) model to evaluate the effect of transient elevation of cytokines, particularly IL-6, on CYP450 suppression. The predicted suppression of hepatic CYP450 activities was <30%, and IL-6-mediated changes in exposure to sensitive substrates of CYP3A4, CYP1A2, and CYP2C9 were
RESUMO
A case of a medullary carcinoma of the thyroid gland that secreted both calcitonin and adrenocorticotropin (ACTH) is reported. The patient was a 32-year-old man who was referred to the Clinical Center of the National Institutes of Health with radiologic evidence of intrathoracic and hepatic masses accompanied by florid Cushing's syndrome. Serum levels of calcitonin and ACTH were elevated. The thoracic and hepatic masses were resected. The histologic findings were typical of medullary carcinoma of the thyroid with extensive metastases to the liver. The neoplasm had a predominantly solid pattern, and the neoplastic cells were either round or spindled, many with cytologic atypia. Immunohistochemical analysis of fixed, paraffin-embedded sections demonstrated chromogranin, calcitonin, and ACTH in the neoplastic cells. The immunostaining for chromogranin was intense in all of the cells, whereas weaker staining for calcitonin and ACTH was present in scattered cells. Electron microscopy revealed sparse secretory granules in the majority of tumor cells; a minority of neoplastic cells contained numerous granules. We further characterized this neoplasm by performing dual immunohistochemical analysis. This technique clearly demonstrated the presence of ACTH and calcitonin within the same neoplastic cells. Thus, the medullary carcinoma of the thyroid in this patient was the source of ectopic ACTH secretion causing Cushing's syndrome. In addition, this report highlights the value of using double immunostaining to localize both the ACTH and calcitonin within the same cells.
Assuntos
Síndrome de ACTH Ectópico/complicações , Carcinoma/complicações , Síndrome de Cushing/etiologia , Neoplasias da Glândula Tireoide/complicações , Adulto , Calcitonina/metabolismo , Carcinoma/metabolismo , Carcinoma/patologia , Humanos , Técnicas Imunoenzimáticas , Masculino , Microscopia Eletrônica , Neoplasias da Glândula Tireoide/metabolismo , Neoplasias da Glândula Tireoide/patologiaRESUMO
The observation that neuroectodermal differentiation imparts a worse prognosis to the Ewing family of tumors has been suggested by some studies and refuted by others. To assess whether the diagnosis of Ewing's sarcoma versus peripheral primitive neuroectodermal tumor (PNET) affects prognosis, we analyzed tumors from 63 analogously treated pediatric and young adult patients from the National Cancer Institute and St Jude Children's Research Hospital and retrospectively compared the results with clinical outcomes. The tumors were assessed using standard light microscopy and immunohistochemical stains for neuron-specific enolase, CD57, S100 protein, neurofilament protein, and synaptophysin with or without antigen retrieval. Ultrastructural evaluation was also performed in 39 tumors. Classification was performed using Kiel criteria as well as a modified classification. Kaplan-Meier analyses, with Mantel-Haenzel evaluation of the significance of the differences, were performed separately for localized or metastatic tumors. Using the Kiel classification on a subset of 60 cases, 39 tumors qualified as PNET and 21 as Ewing's sarcoma. Using the modified classification on a subset of 61 cases, 14 were classified as PNET, 21 as atypical Ewing's sarcoma, and 26 as Ewing's sarcoma. The addition of electron microscopy to the diagnostic armamentarium significantly increased the likelihood of identifying PNET. No significant differences in event-free or overall survival were seen using either the modified or Kiel classification, regardless of the ancillary diagnostic techniques employed. In this exploratory analysis, neuroectodermal differentiation did not play a role in clinical outcome. Confirmation of this finding will require a larger, separate study of similarly treated patients, and it may not apply to older patients.
Assuntos
Tumores Neuroectodérmicos Primitivos/patologia , Sarcoma de Ewing/patologia , Adolescente , Adulto , Antígenos de Diferenciação/metabolismo , Diferenciação Celular , Criança , Pré-Escolar , Intervalo Livre de Doença , Ectoderma/citologia , Feminino , Humanos , Imuno-Histoquímica , Lactente , Masculino , Tumores Neuroectodérmicos Primitivos/metabolismo , Tumores Neuroectodérmicos Primitivos/mortalidade , Estudos Retrospectivos , Sarcoma de Ewing/metabolismo , Sarcoma de Ewing/mortalidade , Taxa de SobrevidaRESUMO
The authors evaluated P-glycoprotein expression in a total of 35 cases of Ewing's sarcoma and peripheral primitive neuroectodermal tumors (PNET). Fifteen cases had matched tumors before and after treatment. The 20 unmatched tumors included 14 pretreatment PNETs and Ewing's sarcomas and 6 posttreatment Ewing's sarcomas. Two antibodies, C219 and JSB-1, were used. Immunoreactivity was almost exclusively membranous. Variability in the number of positive cells and in staining intensity was noted within individual tumors. Among the 15 matched tumors, 7 were positive for P-glycoprotein before treatment; 6 of these remained positive after treatment. Four of the 8 that were negative for P-glycoprotein before treatment became positive after treatment. Of the unmatched tumors, 9 of 14 pretreatment and 3 of 6 posttreatment tumors were positive. When relapse-free survival time, based on the presence or absence of P-glycoprotein positivity in pretreatment tumor samples, was evaluated in this group, no significant difference was found (P2 = .92); however, the numbers are too small to draw definitive conclusions. The high incidence of positive primary tumors suggests that P-glycoprotein expression is probably intrinsic in Ewing's sarcoma and PNET and not necessarily induced by therapy.
Assuntos
Proteínas de Transporte/análise , Glicoproteínas de Membrana/análise , Proteínas de Neoplasias/análise , Tumores Neuroectodérmicos Primitivos Periféricos/química , Tumores Neuroectodérmicos Primitivos Periféricos/tratamento farmacológico , Sarcoma de Ewing/química , Sarcoma de Ewing/tratamento farmacológico , Membro 1 da Subfamília B de Cassetes de Ligação de ATP , Resistência a Medicamentos , Humanos , Técnicas Imunoenzimáticas , Recidiva , Análise de SobrevidaRESUMO
Epithelioid hemangioendothelioma (EH) is a vascular neoplasm of uncertain malignant potential. We report a 22-yr-old female with a primary malignant EH of the iliac bone with adjacent soft tissue involvement which, during its metastatic course, presented as a pleural effusion. The effusion was cellular with tumor cells present both singly and in clusters. Distinguishing cytologic features included cytoplasmic vacuolization consistent with primitive intracytoplasmic lumen formation, variability in cell size, biphasic cytoplasmic staining with Diff-Quik stain, multinucleation, cell in cell engulfment, and multiple prominent nucleoli. Differential diagnosis based on morphology included malignant mesothelioma and adenocarcinoma. Immunocytochemical stains on the neoplastic cells were positive for Ulex Europaeus, Factor VIII-related antigen, and CD34, reflecting vascular differentiation and confirming the diagnosis of metastatic EH to the pleural cavity.
Assuntos
Hemangioendotelioma Epitelioide/patologia , Hemangioendotelioma Epitelioide/secundário , Neoplasias Pulmonares/secundário , Derrame Pleural Maligno/patologia , Adulto , Técnicas Citológicas , Feminino , Hemangioendotelioma Epitelioide/química , Humanos , Técnicas Imunoenzimáticas , Neoplasias Pulmonares/complicações , Derrame Pleural Maligno/etiologiaRESUMO
Mantle cell lymphoma (MCL) is a rare type of non-Hodgkin's lymphoma which is thought to derive from the cuff of the lymphoid follicle. The histopathologic and immunophenotypic features of MCL are well described. The literature contains few cytopathologic studies of collected cases of MCL. Review of files from the National Institutes of Health from 1989 through June 1993 revealed a total of 24 positive specimens from eight patients with a diagnosis of MCL. The specimens consisted of ten pleural effusions, ten cerebrospinal fluids (CSF), and four fine-needle aspirations. CSF involvement was noted in 3 of 8 (37.5%) patients and was associated with disease progression. The cardinal morphologic features on air-dried, Diff-Quik-stained material are a monotonous population of relatively small atypical lymphoid cells with enlarged, frequently grooved nuclei, coarse chromatin and small nucleoli, scant cytoplasm, and an absence of large or "transformed" lymphoid cells. Immunocytochemistry is characterized by expression of one or more pan-B-cell markers, immunoglobulin light-chain restriction, and positivity for the pan-T-cell antigen CD5. When these morphologic and immunocytochemical characteristics are present, the specific diagnosis of MCL can be suggested on cytologic specimens.
Assuntos
Linfoma não Hodgkin/química , Linfoma não Hodgkin/patologia , Adulto , Idoso , Antígenos CD20/análise , Antígenos CD5/análise , Feminino , Humanos , Imuno-Histoquímica , Linfoma não Hodgkin/imunologia , Masculino , Pessoa de Meia-IdadeRESUMO
Photodynamic therapy (PDT) has been used in phase I clinical trials at the National Institutes of Health for the treatment of malignancies disseminated within the peritoneal and pleural cavities. Review of records revealed 18 patients who were treated with PDT between April 1988-June 1993. Sixty-five pleural and peritoneal fluids, 22 pre- and 43 post-PDT, were available for evaluation. Mesothelial cell changes seen post-PDT included: increased nuclear-to-cytoplasmic ratios in 7/18 (39%), cytomegaly in 9/18 (50%), and multinucleation in 12/18 (67%), with Touton-like giant cells in 3/18 (17%). Additional changes noted post-PDT comprised histiocytic aggregates in 9/18 patients (50%), with granuloma-like clusters in 3/18 (17%), acute and chronic inflammation in 13/18 (72%), and eosinophilia in 8/18 (44%). Residual tumor was present in 7/18 (39%) patients post-PDT. In 2 patients with malignant mesothelioma, benign mesothelial cells with cytologic changes post-PDT were difficult to distinguish from malignant cells. Mesothelial cell changes following PDT, specifically increased nuclear-to-cytoplasmic ratios and cytomegaly, should be recognized to avert false-positive diagnoses of tumor. In patients with malignant mesothelioma, and less commonly with adenocarcinoma, benign mesothelial cells with changes secondary to PDT may be difficult to distinguish from tumor cells.
Assuntos
Cavidade Peritoneal/citologia , Fotoquimioterapia , Derrame Pleural Maligno/patologia , Derrame Pleural/citologia , Estudos de Avaliação como Assunto , Humanos , Estudos RetrospectivosAssuntos
Mesotelioma/secundário , Glândula Parótida/patologia , Neoplasias Parotídeas/secundário , Neoplasias Pleurais/patologia , Biomarcadores Tumorais/análise , Biópsia por Agulha , Carcinoma/diagnóstico , Diagnóstico Diferencial , Humanos , Masculino , Mesotelioma/química , Mesotelioma/diagnóstico , Mesotelioma/patologia , Pessoa de Meia-Idade , Proteínas de Neoplasias/análise , Neoplasias Parotídeas/química , Neoplasias Parotídeas/diagnóstico , Neoplasias Parotídeas/patologiaRESUMO
The drug development process is divided into phases with decisions required on compound selection and promotion to each subsequent development phase. In preclinical drug development the main objective is to bring the compound into human trials and there is an inability of many preclinical information packages to predict clinical responses. Since clinical responses are functions of the dose, the human dose anticipation should be a key deliverable of any preclinical package of drug candidate. The human dose should be anticipated by integration of information from multiple sources, in vitro and in vivo, non-human and human, using a variety of methodologies and approaches. Prediction of human safe and active dose relies on the availability of validated animal models for effect. Although there are many exceptions to the rule, the paper defines a four-step approach for the anticipation of human dose for first-in-man trials: 1, characterization of non-human exposure-response relationships; 2, correction for interspecies differences; 3, diagnosing compound absorption, distribution, metabolism and excretion (ADME) properties and prediction of human pharmacokinetics; and 4, prediction of human dose-responses and dose selection for phase I protocols.
Assuntos
Desenho de Fármacos , Animais , Transporte Biológico Ativo , Ensaios Clínicos Fase I como Assunto/métodos , Humanos , Técnicas In Vitro , Modelos Biológicos , Preparações Farmacêuticas/administração & dosagem , Xenobióticos/administração & dosagem , Xenobióticos/farmacocinética , Xenobióticos/farmacologiaRESUMO
Microsporidia are now recognized as important pathogens of AIDS patients; the ability of these parasites to cause disease in immunocompetent persons is still being elucidated. Improved diagnostic tests for microsporidial infection are continually being sought for establishing diagnosis in order to avoid laborious electron microscopy studies that require invasively acquired biopsy specimens. Modified trichrome or chemofluorescent stains are useful for detecting microsporidia in bodily fluids and stool specimens, but they do not allow for speciation of microsporidia. Polymerase chain reaction with specific primers will allow the detection and speciation of microsporidia in biopsy tissue, bodily fluids, and stool specimens.
Assuntos
Microsporida/patogenicidade , Microsporidiose/diagnóstico , Animais , Genes de Protozoários , Humanos , Microscopia Eletrônica , Microsporida/genética , Microsporida/isolamento & purificação , Reação em Cadeia da PolimeraseRESUMO
MART-1 is a transmembrane protein that appears to be melanocyte specific. This study evaluated the use of a new monoclonal antibody, directed against MART-1, in fresh and paraffin-embedded specimens. Twenty-three paraffin-embedded tumors were evaluated for MART-1 immunoreactivity both before and after microwave-based antigen retrieval. After this comparison, 53 fine-needle aspirates from 43 patients with malignant melanoma were assessed for MART-1 immunoreactivity. Immunocytochemistry was performed on both cytospins and paraffin-embedded tissues that were pretreated with antigen retrieval. Seventeen (74%) of 23 tumors evaluated for immunoreactivity before and after antigen retrieval showed a significant increase in both staining intensity and the number of cells stained. When cytospins and antigen-retrieved cell blocks from 53 fine-needle aspirates were compared. 38 (72%) showed good correlation. In 13 (25%) of 53 tumors, MART-1 immunoreactivity was more intense in the cytospins, although the differences were marked in only two cases: Microwave-based antigen retrieval renders paraffin-embedded tissues nearly as sensitive as fresh material for use in the immunocytochemical detection of MART-1. This technique will allow the evaluation of MART-1 immunoreactivity in archival malignant melanomas.
Assuntos
Antígenos de Neoplasias/análise , Melanoma/imunologia , Proteínas de Neoplasias/análise , Anticorpos Monoclonais , Humanos , Imuno-Histoquímica , Antígeno MART-1 , Inclusão em Parafina , Manejo de Espécimes/métodosRESUMO
BACKGROUND: The distinction between malignant mesothelioma (MM) and adenocarcinoma (ACA) in cytologic specimens frequently is difficult, often requiring immunocytochemistry to support the diagnosis. Recent reports have proposed the utilization of antibodies to mesothelial cell clone HBME-1 and thrombomodulin (TM), because they are immunoreactive in MM and less commonly reactive in ACA. Immunoreactivity for the monoclonal antibody CA 19-9 has been observed in many ACAs and reportedly is absent in MM. METHODS: In this study, immunostaining was performed on formalin fixed, paraffin embedded cell blocks from effusions or fine-needle aspirations using the avidin-biotin-peroxidase method. Thirty-eight MMs and 49 ACAs were tested using antibodies to CA 19-9, HBME-1, and TM. RESULTS: Anti-CA 19-9 stained only 1 of the 37 cases of MM tested (3%), but stained 24 of the 49 cases of ACA (49%). Anti-HBME-1 stained 34 of 38 cases of MM (89%), and 28 of 43 cases of ACA tested (65%). Anti-TM stained 24 of 36 cases of MM (67%), and 21 of 40 cases of ACA tested (53%). CONCLUSIONS: CA 19-9 has utility as part of an immunocytochemical panel for distinguishing ACA from MM, because a positive staining reaction would make the diagnosis of MM unlikely. Although HBME-1 and TM can identify MM positively, each frequently is detected in ACA, thus limiting the utility of these antibodies in cytologic specimens.
Assuntos
Adenocarcinoma/diagnóstico , Anticorpos Monoclonais/análise , Antígenos de Neoplasias/imunologia , Antígeno CA-19-9/imunologia , Mesotelioma/diagnóstico , Neoplasias Pleurais/diagnóstico , Trombomodulina/análise , Adenocarcinoma/patologia , Biópsia por Agulha , Diagnóstico Diferencial , Reações Falso-Positivas , Humanos , Imuno-Histoquímica , Mesotelioma/patologia , Derrame Pleural/diagnóstico , Neoplasias Pleurais/patologia , Sensibilidade e EspecificidadeRESUMO
Oncocytic neoplasms are most commonly of salivary, thyroid, parathyroid, and renal origin. Ocular adnexal tumors with oncocytosis have been reported. We report an unusual example of a skin adnexal tumor from the back. A tumor of uncertain duration was excised from a 54-year-old man. Light microscopy of hematoxylin and eosin-stained sections showed a large, fairly well-defined cystic nodular hidradenoma with areas infiltrated by numerous closely arranged, large, uniform, oval and polygonal cells with abundant intensely eosinophilic cytoplasm and small central, dark, round nuclei. No significant cellular atypia or mitotic figures were observed. The cytoplasm of these cells showed markedly positive immunostaining with monoclonal antimitochondrial antibodies. Electron microscopy demonstrated cytoplasm packed with mitochondria. Pure oncocytic tumors usually follow a benign clinical course. The focal presence of oncocytes in an otherwise histologically recognizable tumor apparently does not affect the prognosis, which in this case is the favorable outcome expected for a nodular hidradenoma.
Assuntos
Adenoma de Glândula Sudorípara/patologia , Neoplasias das Glândulas Sudoríparas/patologia , Adenoma Oxífilo/patologia , Dorso , Núcleo Celular/ultraestrutura , Citoplasma/ultraestrutura , Epitélio/patologia , Humanos , Masculino , Pessoa de Meia-Idade , Mitocôndrias/ultraestrutura , Resultado do TratamentoRESUMO
BACKGROUND: Ketamine is used as an anaesthetic agent for short surgical procedures, and as a sedative and analgesic in intensive care patients. Intensive care patients with brain or spinal cord injury may have physiological changes that could alter the pharmacokinetics of ketamine. The pharmacokinetics of ketamine have been studied in healthy volunteers and in patients undergoing different types of surgery, but no data are available in intensive care patients. METHODS: We determined the pharmacokinetics of ketamine and its active metabolites, norketamine and dehydronorketamine, in 12 intensive care patients with brain or spinal cord injury. The effect of ketamine on haemodynamic variables was also investigated. RESULTS: The total clearance of ketamine, mean (SD), was 36.0 (13.3) ml min(-1) kg(-1), the volume of distribution (Vbeta) was 16.0 (8.6) litre kg(-1), and the elimination half-life was 4.9 (1.6) h. Ketamine did not alter any haemodynamic variables in the patients studied. CONCLUSIONS: Pharmacokinetic variables of ketamine in intensive care patients are greater than in healthy volunteers and in surgical patients. The increase in the volume of distribution is greater than the increase in clearance, resulting in a longer estimated half-life of ketamine in this patient group.
Assuntos
Anestésicos Dissociativos/farmacocinética , Lesões Encefálicas/metabolismo , Cuidados Críticos/métodos , Hemodinâmica/efeitos dos fármacos , Ketamina/análogos & derivados , Ketamina/farmacocinética , Traumatismos da Medula Espinal/metabolismo , Adulto , Análise de Variância , Anestésicos Dissociativos/sangue , Anestésicos Dissociativos/farmacologia , Pressão Sanguínea/efeitos dos fármacos , Lesões Encefálicas/terapia , Feminino , Meia-Vida , Frequência Cardíaca/efeitos dos fármacos , Humanos , Ketamina/sangue , Ketamina/farmacologia , Masculino , Taxa de Depuração Metabólica , Pessoa de Meia-Idade , Traumatismos da Medula Espinal/terapiaRESUMO
We conducted a serosurvey among patients of a health center in Hashimiah, a Jordanian town of 30,000 inhabitants located near a wastewater treatment plant and its effluent channel. Serum samples from 261 patients >/=5 years of age were assessed for immunoglobulin G (IgG) and IgM antibodies against West Nile, sandfly Sicilian, sandfly Naples, and Rift Valley viruses; the seroprevalence of IgG antibodies was 8%, 47%, 30%, and 0%, respectively. Female participants were more likely to have been infected than male. Persons living within 2 km of the treatment plant were more likely to have been infected with West Nile (p=0.016) and sandfly Sicilian (p=0.010) viruses. Raising domestic animals within the house was a risk factor for sandfly Sicilian (p=0.003) but not for sandfly Naples virus (p=0.148). All serum samples were negative for IgM antibodies against the tested viruses. Our study is the first documentation of West Nile and sandfly viruses in Jordan and calls attention to the possible health hazards of living close to wastewater treatment plants and their effluent channels.
Assuntos
Anticorpos Antivirais/sangue , Febre por Flebótomos/epidemiologia , Phlebovirus/imunologia , Febre do Nilo Ocidental/epidemiologia , Vírus do Nilo Ocidental/imunologia , Adolescente , Adulto , Animais , Criança , Pré-Escolar , Feminino , Humanos , Jordânia/epidemiologia , Masculino , Febre por Flebótomos/virologia , Prevalência , Estudos Soroepidemiológicos , Febre do Nilo Ocidental/virologiaRESUMO
Submucosal nodules are often encountered during investigations of the upper gastrointestinal (GI) tract. This is particularly true in diseases resulting in chronic hypergastrinemia, such as Zollinger-Ellison syndrome (ZES), in which submucosal gastric and duodenal lesions can occur. Forceps biopsy of submucosal lesions often yields only normal mucosa; however, fine needle aspiration cytology (FNAC) has recently been described as having high diagnostic accuracy for submucosal tumors. Therefore, we prospectively studied the use of FNAC in 43 patients with ZES. Overall, 33% of patients with ZES had nodules. In patients with the sporadic form of ZES, submucosal nodules were found in 18%, whereas submucosal nodules were found in 80% of patients who had ZES in conjunction with multiple endocrine neoplasia type I (MEN-I). FNAC identified 11/12 (92%) of the neuroendocrine tumors, and identified another 8/9 as non-neuroendocrine. Jumbo forceps biopsy was performed on 18 nodules and diagnosed one neuroendocrine tumor. Subsequently, 11 of these nodules were found to possess neuroendocrine tumor; thus only 1/11 (9%) neuroendocrine tumors removed were accurately identified by jumbo forceps biopsy. Of the first 14 nodules, sufficient tissue was left after biopsy to permit snare polypectomy on 12 nodules. Four nodules were found to contain neuroendocrine tumor. Snare polypectomy resulted in a duodenal perforation that required surgery in one patient, and thus was not performed on the final seven nodules.(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Biópsia por Agulha , Síndrome de Zollinger-Ellison/patologia , Biópsia , Endoscopia do Sistema Digestório , Feminino , Mucosa Gástrica/patologia , Humanos , Mucosa Intestinal/patologia , Masculino , Pessoa de Meia-Idade , Neoplasia Endócrina Múltipla/patologia , Estudos ProspectivosRESUMO
A 49-year-old man developed disseminated histoplasmosis 6 1/2 years after transplantation. The organism was initially present in the urine and in a tongue lesion. Treatment with itraconazole was instituted. However, there was further dissemination of the disease and worsening of renal function. Allograft biopsy showed extensive involvement with the organism. Amphotericin B was started, resulting in a rapid resolution of the disease. However, renal function deteriorated, leading to permanent hemodialysis.
Assuntos
Histoplasmose/patologia , Nefropatias/patologia , Falência Renal Crônica/etiologia , Transplante de Rim , Infecções Oportunistas/patologia , Complicações Pós-Operatórias/patologia , Biópsia , Rejeição de Enxerto , Histoplasma/isolamento & purificação , Histoplasmose/complicações , Histoplasmose/microbiologia , Humanos , Rim/microbiologia , Rim/patologia , Nefropatias/complicações , Nefropatias/microbiologia , Falência Renal Crônica/microbiologia , Falência Renal Crônica/patologia , Masculino , Pessoa de Meia-Idade , Infecções Oportunistas/complicações , Infecções Oportunistas/microbiologia , Complicações Pós-Operatórias/microbiologia , Fatores de TempoRESUMO
BACKGROUND: HMB-45, an antibody directed against a premelanosome glycoprotein, has thus far been considered the most specific antibody for the immunocytochemical substantiation of the diagnosis of malignant melanoma (MM). A recently described antigen, MART-1, is a transmembrane protein that is present in normal melanocytes and widely expressed in MM. Antibodies to MART-1 have recently become commercially available. Both HMB-45 and MART-1 form the basis of ongoing immunotherapy protocols at the National Institutes of Health/National Cancer Institute. METHODS: The authors evaluated 207 lesions from 160 patients with metastatic MM procured via fine-needle aspiration (FNA) for expression of MART-1 (clone M2-7C10) and HMB-45 prior to commencement of immunotherapy. FNAs were performed on subcutaneous soft tissue masses (190 lesions), lung (8 lesions), liver (5 lesions), pancreas (3 lesions), and brain (1 lesion). To test the specificity of the monoclonal antibody directed against MART-1, the authors evaluated its reactivity in normal tissues as well as in various nonpigmented neoplasms that are often included in the differential diagnosis of MM. RESULTS: Of all lesions tested, 13 (6%) were negative for both MART-1 and HMB-45. Of all patients tested, 20% had 1 or more lesions that were non-immunoreactive with HMB-45, whereas only 10% had 1 or more lesions that were nonimmunoreactive for MART-1. Eight percent of the lesions tested were negative for MART-1 only, whereas 16% of lesions tested were negative for HMB-45 only. In 35% of the lesions, MART-1 stained more cells than HMB-45. In 13%, MART-1 stained fewer cells than HMB-45, and in 52% both antibodies stained an equivalent number of cells. All samples of normal tissue were negative for staining with MART-1, as were the nonpigmented lesions tested. Melanocytes in normal skin samples stained positively for MART-1. CONCLUSIONS: The MART-1 antibody is a superior immunohistochemical marker for the diagnosis of MM. It has the potential to become the preferred antibody over HMB-45 for the diagnosis of metastatic MM in FNA material, as MART-1 stains a higher percentage of lesions in a higher percentage of patients than does HMB-45.
Assuntos
Anticorpos Antineoplásicos , Antígenos de Neoplasias/imunologia , Melanoma/diagnóstico , Proteínas de Neoplasias/imunologia , Neoplasias de Tecidos Moles/diagnóstico , Anticorpos Monoclonais , Biópsia por Agulha , Diagnóstico Diferencial , Humanos , Técnicas Imunoenzimáticas , Antígeno MART-1 , Melanoma/química , Melanoma/secundário , Antígenos Específicos de Melanoma , Proteínas de Neoplasias/análise , Inclusão em Parafina , Sensibilidade e Especificidade , Neoplasias de Tecidos Moles/químicaRESUMO
PURPOSE: To search for tumor-specific in vitro reactivity by lymphocytes derived from patients with ovarian carcinoma. METHODS: Tumor-infiltrating lymphocytes (TIL) were derived from primary or metastatic solid tumors and tumor-associated lymphocytes (TAL) were derived from ascites from 13 patients with ovarian cancer. TIL or TAL were cultured for approximately 30 to 60 days and studied for phenotype, cytotoxicity, and cytokine secretion in response to autologous tumor stimulation. RESULTS: Twenty-nine bulk TIL or TAL cultures were successfully established from 10 patients using various culture conditions. Thirteen cultures were predominantly CD4+ and 16 were mainly CD8+. In contrast to reports by others, none of the cultures tested were specifically lyric for autologous tumor. Five predominantly CD4+ bulk TIL (from four patients) preferentially secreted tumor necrosis factor-alpha and granulocyte macrophage-colony stimulating factor when stimulated with autologous tumor and not when stimulated by autologous Epstein Barr virus-B cells, fibroblasts, peripheral blood mononuclear cells, or allogeneic HLA matched or mismatched stimulators. This cytokine secretion was found to be MHC class-II restricted in three patients because it was inhibited by the anti-MHC class-II antibody IVA12 and the HLA-DR specific antibody L243. CONCLUSION: We believe these data are the first to suggest that tumor reactive CD4+ lymphocytes exist in some ovarian cancer patients. This finding may be useful in the development of novel immunotherapies for these patients.